The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.

How is TNKase administered?

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.

How Was TNKase approved?

The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.

How Common Are These Strokes?

In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.

TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."

What Are The Symptoms Of Ischemic Strokes?

Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.

Other symptoms include:

• Loss of coordination or clumsiness
• Blurry vision or double vision
• Dizziness or vertigo
• Nausea and vomiting
• Neck stiffness
• Mood swings or sudden personality changes
• Confusion or agitation
• Seizures
• Memory loss (amnesia)
• Headaches which are sudden and severe
• Passing out or fainting
• Coma

Are There Any Warning Signs?

While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.

The Democratic Republic of Congo’s (DRC) Ebola outbreak may have been spreading for months before health authorities officially declared it, raising new questions about why the early warning signs were missed.

According to the World Health Organization (WHO), genetic sequencing indicates that the current outbreak began as early as February 2026, while the DRC officially declared the outbreak on May 15. By then, the virus had already had time to spread through communities in eastern DRC.

The outbreak is being caused by the Bundibugyo virus, a rare Ebola species for which there is currently no approved vaccine or specific course of treatment.

What Were The Early Warning Signs?

One of the major reasons why the current Ebola outbreak expanded within a short period of time was that it not immediately recognised.

Some early patients were reportedly treated for malaria or typhoid, illnesses that can initially cause symptoms such as fever, weakness, vomiting and diarrhoea. Early testing also focused on the more common Zaire strain of Ebola, delaying recognition of Bundibugyo virus.

WHO’s own assessment had already identified an unusual cluster of severe illness and deaths in the Mongbwalu health zone in Ituri Province by early May. A subsequent investigation covering April 15 to May 13 identified 246 suspected cases and 65 deaths across three health zones.

Geographical disadvantage was also one of the reasons. Ituri is affected by armed conflict, population displacement and poor road access. Health workers have faced shortages of protective equipment, while some facilities have struggled because of workers' strikes.

Also read: Nova Scotia's Ebola Trial: Why Is Canada Testing A Vaccine When It Has No Outbreak?

What Is The Current Status Of DRC Ebola Outbreak?

The Ebola outbreak in DRC continues to grow at a rapid pace. The latest government figures cited by WHO and international media show about 4,200 confirmed Ebola cases and at least 1,900 deaths in DRC.

WHO Regional Director for Africa Mohamed Janabi described the situation bluntly: “We are chasing the virus, the virus is ahead of us.”

WHO Director-General Tedros Adhanom Ghebreyesus has also warned that the outbreak is moving faster than the response, with cases doubling in some hotspots. He wrote on on X that “the outbreak is spreading faster than our scale up of the response”, adding that new cases had doubled in some hotspots over the previous week.

Ebola becomes considerably harder to contain once transmission moves beyond identifiable limits. Unlike respiratory viruses, Ebola primarily spreads through contact with infected bodily fluids and contaminated materials. But when patients are not recognised early, they can unknowingly expose others, healthcare workers and caregivers.

Also read: FDA Approves Moderna's First mRNA Flu Vaccine, Marking A Milestone In Influenza Prevention

Effects Of Delayed Recognition

One of the major challenges in this outbreak is that around 60–70% of new cases are reportedly occurring outside known contact chains, making traditional contact tracing much harder. The current outbreak has also unfolded in crowded urban and displacement settings, rather than remaining confined to an isolated rural location.

The 2014–2016 West African Ebola epidemic was officially declared in March 2014, although the first human case was later traced back to December 2013. That outbreak eventually led to more than 11,000 deaths.

Also read: Amid Rapidly Expanding Ebola Outbreak, DR Congo Is Seeing An Alarming Increase In Maternal Deaths; Here's Why

Progress In Bundibugyo Vaccine Development

The WHO is now pushing to accelerate the response, including clinical trials of the Ervebo vaccine, which is licensed against the Zaire strain but may offer some protection against Bundibugyo. Researchers are also developing vaccines specifically targeting Bundibugyo virus.

mRNA-1469 is an investigational vaccine developed using Moderna's messenger RNA (mRNA) platform, the same technology used in its COVID-19 vaccine. The vaccine builds on the company's broader research into filoviruses, the family of viruses that includes Ebola.

A new experimental menopause drug has shown promising results in reducing hot flashes, with the company reporting an 83% reduction in moderate-to-severe episodes in a mid-stage clinical trial.

Shares of Canadian biotechnology company AbCellera surged nearly 40% on Monday after it announced positive results for ABCL635, an experimental non-hormonal treatment for moderate-to-severe vasomotor symptoms associated with menopause.

The Phase 2 study involved 92 women. After four weeks, women who received a single 600-mg dose of ABCL635 experienced an 83% reduction in the frequency of moderate-to-severe hot flashes, equivalent to 8.8 fewer episodes per day from baseline. The placebo group reported a 33% reduction, or 3.5 fewer episodes per day.

The treatment also improved the severity of symptoms, sleep and women's overall assessment of their improvement, according to the company.

The most commonly reported side effects, however, included headache, fatigue and reactions at the injection site.

What Makes This Drug Significant?

ABCL635 takes a different approach from hormone replacement therapy (HRT). It is a non-hormonal antibody treatment that targets the neurokinin 3 receptor, or NK3R, a protein involved in the brain's regulation of body temperature.

During menopause, falling estrogen levels can disrupt the activity of a group of brain cells known as KNDy neurons. This can make the body's temperature-control system overly sensitive, triggering hot flashes. By blocking NK3R signaling, ABCL635 is designed to help restore that balance.

Also read: Lifestyle Genetics And Hormones: Understanding The Interplay Of Risk Factors For Ovarian Cancer

More About The Drug

One of the drug's potential advantages is its dosing. ABCL635 is being developed as a long-acting, once-monthly injection, rather than a daily pill.

AbCellera's chief medical officer Sarah Noonberg said the approach could appeal to women already accustomed to self-injecting medicines and could potentially improve adherence compared to daily dosing.

When the Phase 2 programme began, Noonberg said: “Menopausal symptoms can have a profound impact on quality of life,” adding that the company wanted to assess whether ABCL635 could offer women a safe and effective non-hormonal alternative.

However, the drug is still experimental and has not been approved for clinical use. AbCellera said additional 12-week trial data are expected later this year, which will provide a better picture of how long the benefits last and how the treatment performs over a longer period.

The drug development comes as non-hormonal menopause treatments are gaining popularity. FDA-approved options already include drugs targeting neurokinin pathways, including Astellas' Veozah and Bayer's Lynkuet, giving women alternatives when hormone therapy is unsuitable or not preferred.

Also read: Are Women More Likely To Experience More Severe Neurological Symptoms Of Long COVID Than Men? New Study Finds

Why Menopausal Hot Flashes Can Be Unnerving?

Hot flashes, also known as vasomotor symptoms, are among the most common symptoms of menopause. The Menopause Society says up to 80% of women experience hot flashes or night sweats at some point during the menopause.

A hot flash can begin suddenly, often as an intense wave of heat across the face, neck and chest. It may be followed by sweating, chills, dizziness, anxiety or racing heartbeat. When these episodes happen during sleep, they are known as night sweats.

Frequent hot flashes can repeatedly interrupt sleep, leaving women irritable and fatigued the next day. Poor sleep can then affect concentration, mood and daily functioning, creating a cycle in which one menopause symptom amplifies another.

US President Donald Trump has signed an executive order seeking major changes to the country’s childhood vaccination recommendations, including a proposal to split the measles, mumps and rubella (MMR) vaccine into three separate shots.

The order follows his long-standing view that some vaccines should be given separately over different medical visits.

The order, signed on August 10, calls for childhood vaccines to be administered at separate medical visits whenever possible and narrows the federal recommendations to vaccines against 11 core diseases.

It also directs federal health agencies to develop a plan for separate measles, mumps and rubella vaccines, which are currently not available as individual shots in the US.

Trump described the move as establishing “gold-standard” childhood vaccine recommendations and repeatedly raised the topic of vaccine and autism during the signing ceremony.

However, medical experts and lawmakers have opposed the move, saying that the proposed changes are not supported by new scientific evidence.

Why Does Trump Want To Split The MMR Vaccine?

The MMR vaccine currently protects children against three diseases with a combination shot. Under existing CDC guidance, children receive two doses, generally at 12 to 15 months and again at 4 to 6 years.

The CDC says two doses of measles-containing vaccine are about 97% effective at preventing measles.

He recently increased pressure on Health Secretary Robert F. Kennedy Jr. to identify the cause of autism, something Kennedy had pledged to do with new research unveiled last year.

At a Cabinet meeting last month, Trump asked, "How are you doing on the autism research?" Kennedy replied, "We will have an answer for you."

Dr. Andrew Racine, president of the American Academy of Pediatrics, said the announcement could create unnecessary uncertainty for families.

“Science about vaccines and their efficacy has not changed,” Racine said.

Also read: Alexandria Ocasio-Cortez Plans To Freeze Eggs As She Eyes 2028 US Presidential Run

The Problem With Three Separate Shots

One of the biggest hurdles in implementing tis proposal is that individual measles, mumps and rubella vaccines are not currently available in the US.

Dr. Elizabeth Mack, a pediatric critical care physician, questioned how such a system would work.

“We don't have a system that supports this,” she said, raising questions about additional appointments and insurance coverage.

Merck, which manufactures the MMR vaccine, also said there is no published scientific evidence showing a benefit from splitting the combination vaccine. More injections and additional appointments could instead increase the chances of delayed or missed vaccinations.

Also read: Dr. Erica Schwartz Confirmed As CDC’s First Permanent Director In Nearly A Year

How Will This Impact Children?

Doctors are particularly concerned about separating the vaccines and keeping them too far apart. When children need multiple visits to receive protection against different diseases, there can be longer periods during which they remain unprotected.

Public health experts warn this could become especially problematic during outbreaks of diseases that can be prevented by vaccines.

The order also seeks to encourage states to reconsider vaccination requirements for schoolchildren, although states retain authority over school vaccine schedules.

The latest order follows earlier efforts by the Trump administration to overhaul the federal childhood vaccine schedule. In January, Kennedy’s Health and Human Services Department attempted to remove several vaccines from routine childhood recommendations.

That move was challenged in court and blocked by a federal judge. The new executive order seeks to reinforce the administration’s approach while that legal battle continues.

Republican Senator Bill Cassidy, a physician and chairman of the Senate health committee, also criticised the latest move. “I’m a doctor. This executive order is wrong,” Cassidy said. “The President does not have the expertise to make these changes.”